Lung Cancer

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

Dr. Daniel J. Boffa shared how cancer care teams support patients in quitting smoking and how new data may guide improvements in high-smoking U.S. regions.

Lung cancer remains the leading cause of cancer-related deaths in the U.S.

LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.

Lung Cancer Initiative proudly participated in the GO2 Voices Summit held March 9–11, 2025, in Washington, DC.

Dr. Daniel J. Boffa discusses the link between smoking cessation and increase in survival for people who are active smokers and diagnosed with cancer.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.

The strongest connections I’ve made are with others who have also been through their own cancer journeys.

Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.

Enrollment and initial dosing of PAS-004 at 30 milligrams has begun in three patients with MAPK pathway-driven advanced solid tumors.

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

Dr. Douglas Reznick shares advice for patients with lung or head and neck cancer who may feel overwhelmed by their diagnosis.

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

The addition of smoking status to the National Cancer Database might inform more effective treatment for smokers with cancer.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.